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   Most neurologists, vascular neuroradiologists and stroke physicians encounter 
carotid  artery  dissection  (CAD)  regularly,  yet  its  management  remains 
challenging. The main goal is prevention of ischaemic stroke in the territory of 
the affected artery, usually due to thromboembolism, but also potentially due to 
critically  reduced  flow  in  the  dissected  arterial  segment,  so-called 
haemodynamic stroke.   Unfortunately, randomized controlled trial evidence is 
not available regarding the optimal medical treatment of extracranial dissection:  
antiplatelet agents or anticoagulants are both considered reasonable options (1).  
 
Why  is  carotid  dissection  still  a  treatment  challenge?  First,  like  stroke  itself, 
carotid  dissection  is  not  one  disease.  The  aetiology  (traumatic  versus 
spontaneous)  site  of  dissection  (intracranial  versus  extracranial),  degree  of 
luminal  stenosis  and  intracranial  collateral  circulation  varies  from  patient  to 
patient,  with  profound  effects  on  risk,  distribution  and  extent  of  resultant 
cerebral infarction. Second, although CAD accounts for about 20% of ischaemic 
strokes  in  younger  people,  recent  randomized  trials  in  CAD  had  major 
recruitment  difficulties  (1),  suggesting  that  a  definitive  answer  regarding 
optimum medical treatment is unlikely to emerge in the foreseeable future.  
 
Where  patients  with  CAD  have  threatened  or  recurrent  secondary 
thromboembolic or haemodynamic cerebral ischaemia despite adequate medical 
therapy, or where medical treatment is contraindicated, there is considerable 
interest  in  endovascular  treatments.  Similarly  to  endovascular  treatment  of 
atherosclerotic carotid stenosis, a transarterial stent may be inserted with the 
aim  of  either  restoring  adequate  luminal  calibre  or  stabilizing  a  carotid 
pseudoaneurysm  (itself  a  potential  source  of  thromboemolism).  These 
techniques are well established, with first reported carotid stent treatment for 
arterial dissection by Matsuura et al in 1997 (2). High technical success rates 
have been reported in a number of subsequent small case series, well reviewed 
by Xianjun et al in 2013 (3). There are specific technical challenges in selecting 
the true lumen in the dissected vessel and in preventing distal embolisation of 
thrombus from the dissection flap. Current data suggests a procedural morbidity 
of approximately 5% (3,4,5).  Such studies seem liable to selection or publication 
bias, however, and true complication rates may be higher. 
 
In  this  issue  of  Practical Neurology,  Korya  and  colleagues  describe  a  case  of 
extracranial carotid dissection with recurrent transient symptoms in the affected 
hemisphere, which the authors convincingly suggest were due to haemodynamic 
failure (i.e. reduced perfusion) resulting from the tight carotid artery stenosis. 
The patient had experienced transient focal neurological symptoms, related to 
posture and with a low systemic blood pressure, supporting the idea of reduced 
cerebral perfusion, rather than thromboembolism, as a mechanism. The patient’s 
symptoms stopped after a radiologically successful stenting procedure.  
 
Although there is very limited high quality evidence for the effectiveness of acute 
carotid  artery  stenting  in  dissection,  this  case  highlights  its  potential  role  in 
carefully  selected  cases  where  haemodynamic  ischaemia  seems  to  be  the 
dominant problem. Of course, we can never know what would have happened without endovascular treatment, and given the rarity of this clinical situation, a 
randomized controlled trial will not be possible.  
 
This case illustrates the challenges of treating uncommon cases in the field of 
stroke  medicine.  If  a  strictly  evidence-based  approach  is  taken,  this  patient 
should be managed with antithrombotic treatment only (either antiplatelets or 
anticoagulants). However, in this particular case, there was strong evidence for a 
haemodynamic  mechanism  for  the  recurrent  symptoms,  presumably  with  a 
substantial risk of early ischaemic stroke (although this is difficult to quantify) 
(6).  The patient’s attacks had continued despite antithrombotic therapy, and 
logical reasoning suggests that escalating the antithrombotic treatment further 
will  not  help  the  situation.  In  such  exceptional  cases,  it  seems  reasonable  to 
consider endovascular treatment.   
 
But it is important that both doctors and patients appreciate the uncertainties 
and hazards of this course. Every effort should be made to systematically collect 
data on outcomes from such interventions, but the multidisciplinary approach to 
endovascular  treatment  can  make  this  challenging;  in  the  UK,  for  example, 
several carotid stent databases have been initiated in recent years, but none are 
currently comprehensive. Prospective outcome data should ideally be collected 
on all neuro-endovascular procedures undertaken outside randomized trials.  
 
Although “do no harm” is a good starting point for all treatment decisions, this 
case report reminds us that in rarer clinical situations, evidence-based medicine 
will  not  always  give  the  answer,  and  that  careful  consideration  of  the 
pathophysiology, and technical skill, can lead to a good outcome. 
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